Literature DB >> 17447854

Isotype class switching after transplantation in multiple myeloma.

V Maisnar1, M Tichý, L Smolej, P Zák, J Radocha, V Palicka, J Malý, V Bláha.   

Abstract

Switching of the paraprotein isotype or transient presence of oligoclonal bands detectable by serum immunofixation electrophoresis has been reported following not only transplantations, but also after intensive chemotherapy for leukemia. Retrospective analysis of 72 transplanted myeloma patients was carried out to determine the frequency and clinical significance of the appearance of abnormal proteins bands (APB) distinct from the original paraprotein. APB presence was observed in 31 patients (43%) already after the first autotransplant, the median interval from transplant was 2 months (range, 1 to 6 months). The most frequent occurrence of APB was observed after allogeneic transplantation. In the group of patients with APB presence more patients achieved complete remission (32.2% versus 17.1%), statistically significant differences were also established when we compared the percentage of surviving patients and overall survival, to the present date, among both groups of patients (p=0.03). All relapsed patients with previous isotype class switching had disease characterized by the same type of paraprotein as that detected at diagnosis. The development of APB is likely related to the recovery of impaired immunoglobulin production after transplantation. We confirmed favourable prognostic significance of this finding in transplanted myeloma patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17447854

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.

Authors:  Rishi K Wadhera; Robert A Kyle; Dirk R Larson; Angela Dispenzieri; Shaji Kumar; Hillard M Lazarus; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

3.  Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation.

Authors:  Sara L Hall; Jill Tate; Devinder Gill; Peter Mollee
Journal:  Clin Biochem Rev       Date:  2009-08

4.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

5.  High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.

Authors:  Yuanyan Tang; Haisen Yin; Xinying Zhao; Dan Jin; Yan Liang; Tao Xiong; Lu Li; Wen Tang; Jiangzhao Zhang; Min Liu; Zhuojun Yu; Huimin Liu; Sibin Zang; Zhiping Huang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-03

6.  Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma.

Authors:  Zhiyu Liang; Ping Li; Liqing Kang; Lili Zhou; Yang Xu; Shiguang Ye; Juan Du; Bing Li; Yiwen Wang; Lei Yu; Wenbin Qian; Aibin Liang
Journal:  Blood Adv       Date:  2022-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.